US 11892450
Evaluation, assays and treatment of pKal-mediated disorders
granted A61PA61P1/02A61P1/04
Quick answer
US patent 11892450 (Evaluation, assays and treatment of pKal-mediated disorders) held by Takeda Pharmaceutical Company Limited expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61P, A61P1/02, A61P1/04, A61P1/14, A61P11/00